OpenResearchAlpha

Cephalalgia · 17 Nov 2026

Sustained response to atogepant in episodic and chronic migraine: Post-hoc analyses of ELEVATE and PROGRESS, and their open-label extension

Soo-Jin Choh-index 32, Deborah I. Friedman, Natty Chalermpalanupap, Stephanie J. Nahas, Brett Dabruzzo, Umer Najib, Yingyi Liu, Karen Carr, Fumihiko Sakai, Jonathan H. Smith, Patricia Pozo-Rosichh-index 31

0
Citations
no database records one yet
0
Citations in 2026
so far
32
Leading author's h-index
Soo-Jin Cho, in QAI's scholar index
34
References
works it cites, from open citation data

Citations by database

Each database indexes a different set of journals, preprints and books, so they are shown side by side rather than blended.

  • OpenCitations0
  • Crossref0
  • Europe PMC0

Citations per year

The current year is still counting.

  • 2026 so far0

Abstract

Background These post-hoc analyses evaluated the proportions of participants who experienced sustained responses to atogepant, an oral calcitonin gene-related peptide receptor antagonist, over two 3-month, double-blind, randomized controlled trials (RCTs) (ELEVATE and PROGRESS) and a 12-month interim analysis of the open-label extension (OLE) study that was composed of participants from ELEVATE and PROGRESS. Methods Post-hoc analyses were conducted to assess the sustained responses with atogepant 60 mg once daily (QD). Sustained responses, based on predefined thresholds for reductions in monthly migraine days (MMDs) over a specified period, allow for evaluation of long-term efficacy of atogepant. The ELEVATE trial enrolled participants with episodic migraine who had inadequate response to two to four classes of conventional oral preventive medications; the PROGRESS trial enrolled participants with chronic migraine. These post-hoc analyses were conducted in the modified intent-to-treat (mITT) populations for the atogepant 60 mg QD group from the RCTs ELEVATE (151 participants) and PROGRESS (256 participants). An initial response was defined as ≥ 50%, ≥ 75%, or 100% reduction in MMDs from baseline to month 1 of each respective RCT. Proportions of participants who maintained or exceeded their month 1 response threshold through months 2 and 3 of each RCT were calculated. For the OLE, (ELEVATE, 240 participants and PROGRESS, 284 participants in the mITT population), initial response was defined as ≥ 50%, ≥ 75%, or 100% reduction in MMDs from baseline to month 4 of the OLE. Proportions of participants who maintained or exceeded their month 4 response threshold at month 12 of the OLE were calculated. Results In the two 12-week RCTs, 61.3% (49/80) of ELEVATE participants and 74.2% (69/93) of PROGRESS participants who experienced an initial ≥ 50% reduction in MMDs during month 1 of each RCT continued to have a ≥ 50% reduction in MMDs during both months 2 and 3. During the OLE, 83.4% (121/145) of participants from ELEVATE and 88.5% (131/148) of participants from PROGRESS who experienced a ≥ 50% reduction in MMDs from the RCT baseline to month 4 of the OLE continued to have a ≥ 50% reduction in MMDs at month 12 of the OLE. High rates of sustained responses were similarly observed across the other response thresholds. Conclusions Participants who experienced an initial clinically meaningful response with atogepant continued to experience sustained responses over the 3-month RCTs as well as at 12 months of their OLE study. Trial registration ELEVATE (3101-304-002), NCT04740827 ( https://clinicaltrials.gov/study/NCT04740827?cond = ELEVATE,%20NCT04740827&rank=1&tab = results ), 2021-02-05; PROGRESS (3101-303-002), NCT03855137 ( https://clinicaltrials.gov/study/NCT03855137?cond = PROGRESS,%20NCT03855137&rank=1&tab = results ); 2019-02-25; Open-label Extension (3101-312-002), NCT04686136 ( https://clinicaltrials.gov/study/NCT04686136?cond = NCT04686136&rank=1 ); 2021-02-19.

What the data shows

  • No database records a citation yet, as is usual for a paper this new.
  • Soo-Jin Cho has the highest h-index among the authors (32).

Graph

This paper in the middle, its authors and their most-cited papers below, the papers it cites to the left and the papers citing it to the right. The timeline lays every paper out by year.

Citing paper shares an authorAuthor without a profileSize shows citations, or h-index for authors

Select a node for its details. Drag to pan, scroll to zoom, drag a node to move it.

Start with

Authors (11)

Each author's standing in QAI's scholar index: the works their ORCID iD is attached to, and for anyone whose ORCID record names a lab OpenResearch follows, their arXiv preprints matched by name and a shared co-author. Names are as printed on the paper.

ProfileMost-cited paper

Cited by 0 papers

Who cites this paper, from open citation data, with Crossref's record of each; the 100 newest when there are more.

0 shown
No citing papers for this filter.

References (34)

What it cites, from open citation data, with Crossref's record of each.

Sign in to see 14 more references

A free account opens the rest of the citing papers and references on every paper’s page.